Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: Promising effector cells for immunotherapy

Blood

Volumn 99, Issue 9, 2002, Pages 3280-3285

  Wen, Yue Jin ^a   Min, Rui ^a   Tricot, Guido ^a   Barlogie, Bart ^a   Yi, Qing ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IDIOTYPE PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PERFORIN; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; ARTICLE; B LYMPHOCYTE; CELL LYSATE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; EFFECTOR CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; MALE; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL;

EID: 0036565872     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.9.3280     Document Type: Article

References (37)

1. The treatment of multiple myeloma
2. Plasma cell myeloma
3. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
4. Relapse of multiple myeloma after autologous transplantation: Survival after salvage therapy
5. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression
6. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes
7. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma: Long-term results of a clinical trial
8. Cancer vaccines based on the identification of genes encoding cancer regression antigens
9. Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor
10. Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients
11. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses
12. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma
13. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma
14. Idiotypic vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: A feasibility study
15. Idiotype-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II 1 molecules
16. Deletion of idiotype-specific T cells in multiple myeloma
17. The dendritic cell system and its role in immunogenicity
18. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α
19. T-cell stimulation induced by idiotypes on monoclonal immunoglobulins in patients with monoclonal gammopathies
20. Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies
21. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity
22. The expanding universe of T-cell subsets: Th1, Th2 and more
23. T-cell subsets and cytokines in parasitic infections
24. Phenotypic analysis of human myeloma cell lines
25. Myeloma bone marrow plasma cells: Evidence for their capacity as antigen-presenting cells
26. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay
27. Murine dendritic cells pulsed with whole tumor lysates mediates potent antitumor immune responses in vitro and in vivo
28. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
29. Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response
30. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease
31. Diagnostic criteria of multiple myeloma
32. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity
33. Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes
34. Myeloma-reactive allospecific cytotoxic T lymphocytes lyse target cells by the granule exocytosis pathway
35. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: Evidence for their capacity to lyse autologous primary tumor cells
36. Mutation in the Fas antigen in patients with multiple myeloma
37. Selection for drug resistance results in resistance to Fas-mediated apoptosis